Top 46-50
09 June 2011 | News
 |
Synchron Research Services |
Synchron
Research
Services reported an estimated revenue of  63 crore in 2010-11
as compared to previous year’s estimated revenue of 57 crore. It is a leading CRO in India,
which
provides a broad range of clinical research services from phase I to
phase IV, including bioavailability, bioequivalence, pharmacokinetic,
pharmacodynamic studies, dermato-pharmacokinetics, bioanalysis,
statistical analysis, data management and pharmacovigilance. It has a
30-bed facility in Bangkok called Bio-Innova Synchron Research to serve
the Asia Pacific region, which was formed by a joint venture between
Bio-innova and Synchron Research. Synchron also acquired Innovance, an
Ahmedabad-based start-up CRO having a clinical research facility. The
new clinical facility is spread across 18,000 sq ft on a single floor,
with three different volunteer housing areas. The new 80 beds will be
an addition to the already existing 90 beds in the existing facility,
thus totaling to 200 beds across Asia. |
| CMD Dr Shivprakash |
||
|
46
|
Business: Provides clinical research services from phase I to phase IV | |
| Start-up Year: 1998 | ||
| Address:
The Chambers, 3rd Floor, Sarkhej-Gandhinagar Highway, Bodakdev,
Ahmedabad - 380 054 |
||
| Tel: +91-79-26853419, 26840427 Fax: +91-79-26853415 Website: www.synchronresearch.com |
||
| Revenue: 63
crore* |
||
 |
JK Agri Genetics |
JK
Agri
Genetics Limited (JKAL), an erstwhile division of JK Tyre &
Industries, clocked a total turnover of 50.66 crore in 2010-11 when
compared with the last year’s revenue of 32.50 crore. The company is
focused on R&D, production, processing and marketing of hybrid
seeds of sorghum, pearl millet, maize, cotton, rice, sunflower, tomato,
okra and hot pepper. There are many hybrids marketed by the company,
including fast-moving hybrids such as JK 99, JK Durga, JK 666, JK
Indra, JK Varun (555), JK Chamundi. The firm has a team of 15 committed
scientists working on different areas of biotechnology. JKAL is
planning to diversify its research into medicinal and aromatic plants
in core activities such as cultivation, contract farming, varietal
development, quality extract production and chemical & DNA finger
printing. JKAL is building up its R&D as well as marker-assisted
selection with novel traits with the help of biotechnology tools. |
| President Mr P S Dravid |
||
|
47
|
Business: Involved in R&D and
marketing of agri biotech products |
|
| Start-up Year: 1989 | ||
| Address:
1-20-177, 4th Floor, Varun Towers, Begumpet, Hyderabad-500016 |
||
| Tel: +91-40-66316858 Fax: +91-40-27764943 Website: www.jkseeds.net |
||
| Revenue: 50.66
crore* |
||
 |
Wockhardt |
Wockhardt,
the
first company in Asia to launch its recombinant human insulin
product, Wosulin, in 2003, recorded an estimated biotech revenue of 50
crore for 2010-11. In Feb 2011, Wockhardt entered into a strategic
global alliance with Sheffield Bio-Science, a Kerry Group Business from
the US, under which the latter will have exclusive sales and
distribution rights to supply the recombinant insulin to the cell
culture markets worldwide. Wockhardt announced in 2009 that it was
experiencing liquidity crisis and was reportedly facing a debt burden
of more than 3,000 crore. Following this, there were
talks that the
company would sell its biotech division. Companies like Pfizer and
Sanofi Aventis were on the run to acquire this unit, and its valuations
reached a whopping 250 crore. Presently, the firm’s R&D
is based
in Aurangabad & Mumbai; Negma Laboratories in France; Morton Grove
Pharmaceuticals in Illinois, US; Pinewood, Ireland and in UK. |
| Chairman Mr Habil F Khorakiwala |
||
|
48
|
Business: Pharmaceutical and biotechnology business | |
| Start-up Year: 1960 | ||
| Address:
Wockhardt Towers, Bandra Kurala Complex, Bandra (East), Mumbai-400051 |
||
| Tel: +91-22-26596258 Fax: +91-22-26596801 Website: www.wockhardt.in |
||
| Revenue: 50
crore* |
||
 |
Max Neeman International |
Max
Neeman
International, a subsidiary of the Max India Group, registered a
growth of 21 percent from 40 crore in FY 2009-10 to 48.4 crore in FY
2010-11. The firm offers a full range of clinical research services
with focus on phase I-IV trials for drugs, devices, nutraceuticals and
cosmetics in compliance with ICH GCP standards. It is based out of six
regional offices and has 175 active sites in 22 cities, with access to
over 900 GCP trained investigators. Max Neeman is a ISO 9001:2008 and
ISO 27001 certified organization. The number of trials of the firms
reached 200 and the CRO has a total client base of 65 companies across
the globe. Max Neeman has consistently maintained a patient retention
rate of above 98 percent across multiple therapeutic areas for all its
studies. Max Neeman successfully completed four FDA audits for the
highest enrollment globally and has been successfully audited around 40
times by the sponsor companies. |
| CEO Dr Ajoy Kumar |
||
|
49
|
Business: Clinical research services | |
| Start-up
Year: 2001 |
||
| Address: Max House, 1 Dr Jha Marg,
Okhla III, New Delhi-110020 |
||
| Tel: +91-11-40772100 Fax: +91-11-28322846 Website: www.neeman-medical.com |
||
| Revenue: 48.4
crore |
||
 |
Clinigene International |
Clinigene
International,
the full service clinical research arm of biotech major,
Biocon, registered a turnover of 43 crore in FY 2010-11 as compared to
39 crore in the FY 2009-10. In the year
2010, studies conducted by
Clinigene were successfully audited by the USFDA and EMA without Form
483 or critical findings. In addition to the standard service
platforms, the company has identified several more specialized areas,
such as patient-based early studies, complex BA/BE studies and
bio-analytical services, where customers are now seeking CRO support.
The new areas of focus for Clinigene include biomarker development,
data management and pharmacovigilance. Clinigene is India’s first CAP
accredited central laboratory and has also received NABL accreditation.
The company has evolved and adapted its capability platforms and
service offerings against a background of continued macro market
pressures. |
| COO Dr Abhijit Barve |
||
|
50
|
Business: Clinical research | |
| Start-up Year: 1996 | ||
| Address: Clinigene House, Tower 1,
Semicon Park, Electronic City, Phase II, Bangalore-560100 |
||
| Tel: +91-80-28082808 Fax: +91-80-28083150 Website: www.clinigeneintl.com |
||
| Revenue: 43
crore |
||
